Sertraline and low-dose doxepin treatment in severe agitated-anxious depression with significant gastrointestinal complaints: Two case reports

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 13, Issue 4, 2011, Pages 14-

  MacLean, Lisa ^a   Ahmedani, Brian K ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; ATROPINE; BENZODIAZEPINE; BROMIDE; BUSPIRONE; CITALOPRAM; CLONAZEPAM; DIAZEPAM; DOXEPIN; ESCITALOPRAM; FAMOTIDINE; HYOSCYAMINE; LORAZEPAM; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PHENOBARBITAL; PROCHLORPERAZINE; QUETIAPINE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIAZOLAM; ZOLPIDEM;

ADULT; AGITATED DEPRESSION; ANXIETY DISORDER; BEDTIME DOSAGE; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; RECURRENT DISEASE; REMISSION; SEDATION; SIDE EFFECT; TREATMENT DURATION;

EID: 80053065488     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.11l01152     Document Type: Letter

References (8)

1. Olgiati P, Serretti A, Colombo C. Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression. Depress Anxiety. 2006;23(7):389-397. PubMed doi:10.1002/da.20191
2. Hamilton M. Distinguishing between anxiety and depressive disorders. In: Last SCA, Hersen M, eds. Handbook of Anxiety Disorders. New York, NY: Pergamon Press; 1988:143-145.
3. North CS, Hong BA, Alpers DH. Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. World J Gastroenterol. 2007;13(14):2020-2027. PubMed
4. Addolorato G, Mirijello A, D'Angelo C, et al. State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. Int J Clin Pract. 2008;62(7):1063-1069. PubMed doi:10.1111/j.1742-1241.2008.01763.x
5. Lydiard RB, Falsetti SA. Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am J Med. 1999;107(5A):65S-73S. PubMed doi:10.1016/S0002-9343(99)00082-0
6. Dunbar GC, Fuell DL. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol. 1992;6(suppl 4):81-90. PubMed doi:10.1097/00004850-199206004-00014
7. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000;108(1):65-72. PubMed doi:10.1016/S0002-9343(99)00299-5
8. Vij JG, Jiloha RC, Kumar N, et al. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian J Psychiatry. 1991;33:243-246.